Company intelligence / Profile preview

Spirita Oncology

Natick, Massachusetts, United Statesspiritaoncology.com ↗

Ownership: Private
Employees: ~63
Development stage: Phase 1

Overview

Spirita Oncology is conducting a Phase 1 clinical trial of E6201, a potent MEK1 inhibitor with excellent brain penetration, in combination with dabrafenib in patients with BRAF V600-mutated metastatic melanoma that has spread to the central nervous system. Previous Phase 1 trials showed activity in metastatic melanoma patients, including two patients with brain metastases, one of whom maintained an exceptional ongoing durable response lasting for more than 10 years[3].

Therapeutic areas: Oncology
Modalities: Small molecules (MEK1 inhibitor)
Industry: Biotech

Drug pipeline

1 asset

E6201

Phase 1

Indications: Melanoma brain metastases, Diffuse intrinsic pontine glioma

Partnerships

JS InnoPharm (Shanghai) Ltd.[5]

Beyond the preview

Go deeper on Spirita Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spirita Oncology.

Explore the full profile